The FDA Now Requires Increased MRI Monitoring for Alzheimer’s Patients Who Are Treated with Leqembi
After the death of six patients, the FDA has announced that it will require earlier and more frequent monitoring of the monoclonal antibody Leqembi, the brand name for the Alzheimer’s…